

# Alan F Schatzberg

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2117936/alan-f-schatzberg-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153  
papers

12,307  
citations

53  
h-index

110  
g-index

168  
ext. papers

14,979  
ext. citations

7.6  
avg, IF

6.44  
L-index

#	Paper	IF	Citations
153	Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. <i>Biological Psychiatry</i> , <b>2007</b> , 62, 429-37	7.9	1650
152	A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1462-70	59.2	985
151	Resting-state connectivity biomarkers define neurophysiological subtypes of depression. <i>Nature Medicine</i> , <b>2017</b> , 23, 28-38	50.5	972
150	Genome-wide association study identifies 30 loci associated with bipolar disorder. <i>Nature Genetics</i> , <b>2019</b> , 51, 793-803	36.3	662
149	Major depressive disorder. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16065	51.1	635
148	Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 9950-5	11.5	361
147	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 399-405	14.5	295
146	An open label trial of C-1073 (mifepristone) for psychotic major depression. <i>Biological Psychiatry</i> , <b>2002</b> , 52, 386-92	7.9	261
145	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 1205-1215	11.9	217
144	Rapid reversal of psychotic depression using mifepristone. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 516-21	1.7	214
143	Corticosteroids and cognition. <i>Journal of Psychiatric Research</i> , <b>2001</b> , 35, 127-45	5.2	210
142	A corticosteroid/dopamine hypothesis for psychotic depression and related states. <i>Journal of Psychiatric Research</i> , <b>1985</b> , 19, 57-64	5.2	199
141	Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. <i>Journal of Psychiatric Research</i> , <b>2000</b> , 34, 383-92	5.2	196
140	Prevalence of depressive episodes with psychotic features in the general population. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 1855-61	11.9	180
139	Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1095-100	11.9	173
138	Clinical and biological effects of mifepristone treatment for psychotic depression. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 628-36	8.7	168
137	24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. <i>Archives of General Psychiatry</i> , <b>2000</b> , 57, 755-60		160

136	Cortisol circadian rhythm alterations in psychotic major depression. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 275-81.9	157
135	Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 3568-73	5.6 145
134	Cortisol activity and cognitive changes in psychotic major depression. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1612-6	11.9 131
133	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1592-1603	15.1 125
132	Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. <i>Archives of General Psychiatry</i> , <b>2005</b> , 62, 513-20	110
131	Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. <i>Journal of Consulting and Clinical Psychology</i> , <b>2004</b> , 72, 729-35	6.5 109
130	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 743-50	11.9 106
129	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 716-726	11.9 105
128	A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 365-73	1.7 101
127	Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 233-9	97
126	Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 385-93	7.9 96
125	Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 259-67	8.7 95
124	A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. <i>American Journal of Geriatric Psychiatry</i> , <b>2006</b> , 14, 361-70	6.5 92
123	The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 61, 1-12	5.2 90
122	The neuropsychological profile of psychotic major depression and its relation to cortisol. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 472-8	7.9 89
121	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. <i>Life Sciences</i> , <b>1985</b> , 36, 2491-501	6.8 85
120	Current issues in the classification of psychotic major depression. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 877-85.3	82
119	Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. <i>Biological Psychiatry</i> , <b>1989</b> , 26, 565-75	7.9 82

118	Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. <i>Journal of Psychiatric Research</i> , <b>2004</b> , 38, 27-35	5.2	81
117	Post-mortem molecular profiling of three psychiatric disorders. <i>Genome Medicine</i> , <b>2017</b> , 9, 72	14.4	79
116	Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 135-44	1.7	79
115	Postnatal foraging demands alter adrenocortical activity and psychosocial development. <i>Developmental Psychobiology</i> , <b>1998</b> , 32, 285-291	3	79
114	A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1332-42	8.7	71
113	High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. <i>Brain</i> , <b>2018</b> , 141, e18	11.2	68
112	Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 51, 30-6	5.2	66
111	Aberrant brain activation during a working memory task in psychotic major depression. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 173-82	11.9	63
110	The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. <i>British Journal of Psychiatry</i> , <b>1982</b> , 141, 471-4	5.4	63
109	Clozapine response and plasma catecholamines and their metabolites. <i>Psychiatry Research</i> , <b>1993</b> , 46, 139-49	9.9	62
108	Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. <i>PLoS ONE</i> , <b>2012</b> , 7, e35367	3.7	59
107	Dexamethasone increases plasma free dopamine in man. <i>Journal of Psychiatric Research</i> , <b>1984</b> , 18, 217-23	3.2	59
106	Evidence for alterations of the glial syncytial function in major depressive disorder. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 72, 15-21	5.2	57
105	fMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. <i>American Journal of Geriatric Psychiatry</i> , <b>2015</b> , 23, 13-22	6.5	55
104	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1779-1786	15.1	53
103	Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. <i>Psychiatry Research</i> , <b>1987</b> , 20, 143-53	9.9	53
102	ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 751-9	11.9	51
101	Sertraline versus imipramine to prevent relapse in chronic depression. <i>Journal of Affective Disorders</i> , <b>2001</b> , 65, 27-36	6.6	49

100	A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker?. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 69-74	5.2	47
99	Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. <i>Journal of Molecular Neuroscience</i> , <b>2002</b> , 19, 201-6	3.3	47
98	Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. <i>Psychoneuroendocrinology</i> , <b>2009</b> , 34, 1012-8	5	45
97	Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. <i>European Journal of Pharmacology</i> , <b>2008</b> , 583, 358-64	5.3	45
96	FKBP5 polymorphisms and antidepressant response in geriatric depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2010</b> , 153B, 554-560	3.5	44
95	NMDA antagonist treatment of depression. <i>Current Opinion in Neurobiology</i> , <b>2016</b> , 36, 112-7	7.6	43
94	G protein-linked signaling pathways in bipolar and major depressive disorders. <i>Frontiers in Genetics</i> , <b>2013</b> , 4, 297	4.5	43
93	Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 399-407	8.7	40
92	The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 82, 58-67	5.2	40
91	The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. <i>Psychoneuroendocrinology</i> , <b>2013</b> , 38, 115-21	5	38
90	Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200003	3.7	37
89	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 11955-11960	11.5	37
88	Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 46-54	7.9	36
87	The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 537, 462-71	6.5	36
86	Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. <i>World Journal of Biological Psychiatry</i> , <b>2015</b> , 16, 2-11	3.8	35
85	Fibroblast growth factor 9 is a novel modulator of negative affect. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 11953-8	11.5	34
84	Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. <i>Brain Research</i> , <b>2002</b> , 958, 414-22	3.7	34
83	Altered choroid plexus gene expression in major depressive disorder. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 238	3.3	33

82	Mitochondrial mutations in subjects with psychiatric disorders. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127280	3.7	31
81	Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 849-60	8.7	29
80	Pharmacological principles of antidepressant efficacy. <i>Human Psychopharmacology</i> , <b>2002</b> , 17 Suppl 1, S17-22	2.3	29
79	Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. <i>American Journal of Geriatric Psychiatry</i> , <b>2002</b> , 10, 541-50	6.5	28
78	Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. <i>Psychiatry Research - Neuroimaging</i> , <b>2013</b> , 211, 119-26	2.9	27
77	Detecting psychotic major depression using psychiatric rating scales. <i>Journal of Psychiatric Research</i> , <b>2006</b> , 40, 22-9	5.2	26
76	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 251-261	11.9	24
75	Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 505-511	1.7	23
74	Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. <i>Molecular Neuropsychiatry</i> , <b>2018</b> , 3, 157-169	4.9	22
73	Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 176, 141-50	6.6	21
72	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 68	4.2	21
71	Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. <i>Biological Psychiatry</i> , <b>1999</b> , 45, 222-8	7.9	21
70	Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. <i>Biological Psychiatry</i> , <b>1994</b> , 36, 616-21	7.9	21
69	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 64	8.6	20
68	Coping and glucocorticoid receptor regulation by stress inoculation. <i>Psychoneuroendocrinology</i> , <b>2014</b> , 49, 272-9	5	20
67	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 433-440	4.6	20
66	Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. <i>Brain Research</i> , <b>1999</b> , 832, 152-8	3.7	19
65	Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , <b>2021</b> , appiajp202120101429	11.9	18

64	New approaches to managing psychotic depression. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 1, 19-23	4.6	18
63	Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 4, 27-30	4.6	18
62	HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. <i>Schizophrenia Research</i> , <b>2019</b> , 213, 72-79	3.6	17
61	Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey ( <i>Saimiri sciureus</i> ). <i>Journal of Medical Primatology</i> , <b>2000</b> , 29, 42-5	0.7	17
60	Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence?. <i>Addictive Behaviors</i> , <b>2009</b> , 34, 1017-22	4.2	15
59	The Acute and Post-Discontinuation Effects of a Glucocorticoid Receptor (GR) Antagonist Probe on Sleep and the HPA Axis in Chronic Insomnia: A Pilot Study. <i>Journal of Clinical Sleep Medicine</i> , <b>2008</b> , 04, 235-241	3.1	14
58	Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 110, 104420	5	13
57	Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. <i>Nicotine and Tobacco Research</i> , <b>2015</b> , 17, 1126-33	4.9	13
56	Toward a biochemical classification of depressive disorders IX. DST results and platelet MAO activity. <i>British Journal of Psychiatry</i> , <b>1985</b> , 146, 633-7	5.4	13
55	Development of New Psychopharmacological Agents for Depression and Anxiety. <i>Psychiatric Clinics of North America</i> , <b>2015</b> , 38, 379-93	3.1	12
54	Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 657-658	14.5	11
53	Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 493-502	6.6	11
52	Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, e59	20.1	10
51	Cannabis and the Developing Adolescent Brain. <i>Current Treatment Options in Psychiatry</i> , <b>2020</b> , 7, 144-161	3.1	10
50	Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 5	8.6	10
49	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	10
48	The hypothalamic-pituitary-adrenal axis in alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1983</b> , 7, 35-7	3.7	9
47	Connective Tissue Growth Factor Is a Novel Prodepressant. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 555-562	7.9	8

46	Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys. <i>Scientific Reports</i> , <b>2019</b> , 9, 16232	4.9	8
45	The relationship of chronic pain and depression. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 12, 3-4	4.6	8
44	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 342-347	11.9	7
43	Issues encountered in recent attempts to develop novel antidepressant agents. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1345, 67-73	6.5	7
42	Safety and tolerability of antidepressants: weighing the impact on treatment decisions. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68 Suppl 8, 26-34	4.6	7
41	Stress amplifies sex differences in primate prefrontal profiles of gene expression. <i>Biology of Sex Differences</i> , <b>2017</b> , 8, 36	9.3	6
40	Learning to cope with stress modulates anterior cingulate cortex starburst expression in monkeys and mice. <i>Neurobiology of Learning and Memory</i> , <b>2016</b> , 131, 95-100	3.1	6
39	Rapid Detection of the C496G Polymorphism in the CYP2D6 *2 Allele. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 2153-2155	5.5	6
38	Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys. <i>Neurobiology of Stress</i> , <b>2016</b> , 3, 68-73	7.6	6
37	Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 221-223	11.9	6
36	More Thoughts on Intranasal Esketamine: Response to Drevets et al. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 858-859	11.9	5
35	Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 13, 30-7	4.6	5
34	Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 249-250	11.9	4
33	Learning to actively cope with stress in female mice. <i>Psychoneuroendocrinology</i> , <b>2018</b> , 96, 78-83	5	4
32	Reply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 2795-2797	8.7	4
31	New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. <i>CNS Spectrums</i> , <b>2006</b> , 11, 22-7	1.8	4
30	Inference of Cell Type Composition from Human Brain Transcriptomic Datasets Illuminates the Effects of Age, Manner of Death, Dissection, and Psychiatric Diagnosis		4
29	Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 809-819	8.7	4



28	Employing pharmacologic treatment of bipolar disorder to greatest effect. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 15, 15-20	4.6	4
27	Target Population, Dose, and Timing Considerations for Understanding Naltrexone® Subjective Effect: Response to Amiaz. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 251-252	11.9	3
26	Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 356-363	8.7	3
25	Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. <i>CNS Spectrums</i> , <b>2008</b> , 13, 10-2	1.8	3
24	Identification of potential blood biomarkers associated with suicide in major depressive disorder.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 159	8.6	3
23	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. <i>Biological Psychiatry</i> , <b>2016</b> , 80, 84-86	7.9	2
22	Acute and delayed effects of adrenocorticotrophic hormone on dopamine activity in man. <i>Depression</i> , <b>1994</b> , 2, 292-296		2
21	Post-mortem molecular profiling of three psychiatric disorders		2
20	Empirical evidence of the effect of personality pathology on the outcome of panic disorder. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 107, 42-47	5.2	2
19	Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. <i>Psychiatry Research</i> , <b>2018</b> , 269, 733-739	9.9	2
18	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 576-577	11.9	2
17	Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. <i>CNS Spectrums</i> , <b>2008</b> , 13, 3	1.8	2
16	Rigorous Translational Models Are Key to Studying Ketamine® Antidepressant Mechanism: Response to Wang and Kaplin. <i>American Journal of Psychiatry</i> , <b>2019</b> , 176, 412	11.9	1
15	Multisensory modulation of body ownership in mice. <i>Neuroscience of Consciousness</i> , <b>2020</b> , 2020, niz019	3.3	1
14	The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology Bulletin</i> , <b>2018</b> , 48, 64-153	0.9	1
13	Mechanisms of Action of Ketamine and Esketamine. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 1130	11.9	1
12	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. <i>Journal of Clinical Psychiatry</i> , <b>2021</b> , 82,	4.6	1
11	Prevalence, Factor Structure, and Heritability of Avoidant Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , <b>2021</b> , 209, 764-772	1.8	1

10	Clinical use of nefazodone in major depression: a 6-year perspective. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63 Suppl 1, 18-31	4.6	1
9	Introduction: treating depression and anxiety to remission. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 15, 3-4	4.6	1
8	Eberhard H Uhlenhuth. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 3127	8.7	
7	Neurobiologic Foundations of Mood Disorders <b>2015</b> , 341-358		
6	The silver lining of recent effectiveness trials. <i>World Psychiatry</i> , <b>2009</b> , 8, 30-2	14.4	
5	Response to the presidential address. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 1105-7	11.9	
4	Commentary 6. <i>Pharmacotherapy</i> , <b>1984</b> , 4, 324-324	5.8	
3	Neurobiologic Foundations of Mood Disorders 339-353		
2	Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids": Response to Rubinow et al. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 573-574	11.9	
1	Pharmacologic treatments of major depression: are two mechanisms really better than one?. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65 Suppl 4, 3-4	4.6	